Pfizer divests assets to Alvogen
Pfizer has sold assets to Alvogen which include a portfolio of three injectable products and one inhaled solution product, as part of regulatory terms of approval of its acquisition of Hospira. Two are on-market products, clindamycin injection and acetylcysteine inhalation solution. Acetylcysteine will continue to be marketed by Fresenius with Alvogen receiving profit-sharing payments. In addition, Alvogen will acquire two pending ANDAs, voriconazole injection and melphalan injection. Both pending applications represent generic market with limited participation and are expected to launch as early as 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins